公开(公告)号：US07427663B2

公开(公告)日：2008-09-23

申请号：US10567286

申请日：2004-02-23

申请人： Yusong Chen ,  Shu Li

发明人： Yusong Chen ,  Shu Li

IPC分类号： C07K14/00

CPC分类号： C07K14/4716 ,  A61K38/00

摘要： The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and the deoxyribonucleic acid content less than 7.5%. The present invention further provides a method of producing the cardio myopeptidin and the use thereof in producing pharmaceuticals for treating cardiac disorders, specifically the use in producing pharmaceuticals for treating myocardial ischemic and reperfusion injury. The cardio myopeptidin of the present invention can work directly on myocytes, promoting the repair of injuries caused by various reasons, and providing a new way to relieve ischemic and reperfusion injury, and to promote the repair of injured myocardium.

摘要翻译： 本发明涉及从非人健康哺乳动物的心脏中分离的心脏肌肽。 心肌肌肽的分子量小于10000道尔顿，肽含量为75％〜90％，游离氨基酸含量为6％〜15％，核糖核酸含量低于2％，脱氧核糖核酸含量较少 超过7.5％。 本发明还提供了生产心肌肌肽的方法及其在制备用于治疗心脏病的药物中的用途，特别是用于制备治疗心肌缺血和再灌注损伤的药物的用途。 本发明的心脏肌肽可以直接在肌细胞上起作用，促进由各种原因造成的损伤的修复，并提供减轻缺血和再灌注损伤的新方法，并促进损伤心肌的修复。

公开(公告)号：US20080025576A1

公开(公告)日：2008-01-31

申请号：US11492076

申请日：2006-07-25

申请人： Shu Li ,  Jin Wang

发明人： Shu Li ,  Jin Wang

IPC分类号： G06K9/00

CPC分类号： G06K9/00281 ,  G06K9/00308 ,  G06K9/00597 ,  H04N5/232 ,  H04N5/23219 ,  H04N5/23222

摘要： In a method for detecting facial expressions of a portrait photo by an image capturing electronic device, a face captured in the portrait photo is detected. The position and range of the opened and closed facial features are detected, and the facial features within an identified range are magnified according to a specific proportion. A patch of facial features and their surroundings within a specific range is cut according to the magnified identified range, so that the patch can show a change of facial expressions and a specific range of their surroundings. A facial feature classifier is trained by a specific number of opened and closed facial feature samples based on the Adaboost algorithm and used for detecting the facial features in the patch to determine whether the facial feature is situated at an opened state or a closed state.

摘要翻译： 在通过图像拍摄电子设备检测人像照片的面部表情的方法中，检测在肖像照片中捕获的脸部。 检测打开和关闭的面部特征的位置和范围，并且根据特定比例放大识别范围内的面部特征。 根据放大的识别范围切割特定范围内的一些面部特征及其周围环境，以便贴片可以显示面部表情的变化及其周围环境的特定范围。 面部特征分类器基于Adaboost算法由特定数量的开放和闭合的面部特征样本训练，并用于检测贴片中的面部特征，以确定面部特征是处于打开状态还是关闭状态。

公开(公告)号：US20070128279A1

公开(公告)日：2007-06-07

申请号：US11673066

申请日：2007-02-09

申请人： David Edgren ,  Patrick Wong ,  Gurdish Bhatti ,  Shu Li ,  Robert Skluzacek

发明人： David Edgren ,  Patrick Wong ,  Gurdish Bhatti ,  Shu Li ,  Robert Skluzacek

IPC分类号： A61K31/485 ,  A61K9/24 ,  A61K31/16

CPC分类号： A61K9/0004 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2866 ,  A61K9/2886

摘要： A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.

摘要翻译： 公开了一种膜系统，其包括内壁，围绕内壁的流体可渗透的外壁和由膜系统限定的内部隔室，其中内壁的流体渗透性响应于内部隔室内的渗透性芯的渗透压。 还公开了一种包含膜系统的控释剂型，以及用于在延长的时间段内从渗透泵输送渗透活性制剂的方法。

公开(公告)号：US20070031496A1

公开(公告)日：2007-02-08

申请号：US11499008

申请日：2006-08-04

申请人： David Edgren ,  Shu Li ,  Gurdish Bhatti ,  Patrick Wong

发明人： David Edgren ,  Shu Li ,  Gurdish Bhatti ,  Patrick Wong

IPC分类号： A61K9/24

CPC分类号： A61K9/0004

摘要： Disclosed are osmotic dosage forms including an osmotic core; a semi-permeable membrane that surrounds the osmotic core and comprises a blend of a cellulose acetate polymer and an acrylate copolymer; and an exit formed through the semi-permeable membrane. Also disclosed are methods of making and administering such dosage forms.

摘要翻译： 公开了渗透剂型，包括渗透核; 围绕渗透芯并包含醋酸纤维素聚合物和丙烯酸酯共聚物的共混物的半透膜; 以及通过半透膜形成的出口。 还公开了制备和施用这种剂型的方法。

公开(公告)号：US20060165798A1

公开(公告)日：2006-07-27

申请号：US11341251

申请日：2006-01-27

申请人： David Edgren ,  Gurdish Bhatti ,  Shu Li ,  Robert Skluzacek

发明人： David Edgren ,  Gurdish Bhatti ,  Shu Li ,  Robert Skluzacek

IPC分类号： A61K9/24

CPC分类号： A61K9/0004

摘要： Disclosed are oral osmotic dosage forms and methods wherein a semi-permeable membrane of the oral osmotic dosage form includes from about 23 wt % to about 50 wt % of a flux enhancer and from about 0.01 wt % to about 5 wt % of antioxidant, based on the total dry weight of the semi-permeable membrane. Such compositions provide high flux membranes with improved mechanical and transport stability during storage on the shelf.

摘要翻译： 公开了口服渗透剂型和方法，其中口服渗透剂型的半渗透膜包含约23重量％至约50重量％的助熔剂增强剂和约0.01重量％至约5重量％的抗氧化剂，基于 关于半透膜的总干重。 这样的组合物在储存在架子上时具有改善的机械和运输稳定性的高通量膜。

公开(公告)号：US07011527B1

公开(公告)日：2006-03-14

申请号：US10330610

申请日：2002-12-27

申请人： Shu Li

发明人： Shu Li

IPC分类号： A61J5/00

CPC分类号： A61H1/0218 ,  A61H2203/0493

摘要： A sleeping method for a participant having a foot end and a head end including 1)providing a sleeping surface having upper and lower ends, the sleeping surface inclined at least 10–25 degrees from the upper end to the lower end, 2)providing a predetermined unit of time having successive nightly sleep periods, and 3)the participant sleeping on the sleeping surface in a head down position for at least half or other portion of the successive nightly sleep periods, the head down position comprising the participant laying down on the sleeping surface with the legs and feet of the participant disposed toward the upper end of the sleeping surface and the head end of the participant disposed toward the lower end of the sleeping surface, in which the feet end of the participant is upward relative to the head end of the participant.

摘要翻译： 一种用于具有脚端和头端的参与者的睡眠方法，包括1）提供具有上端和下端的睡眠表面，所述睡觉表面从所述上端至下端倾斜至少10-25度，2）提供 预定的时间单位具有连续的夜间睡眠周期，以及3）在连续的夜间睡眠期间的至少一半或其他部分，睡眠在睡眠表面上的参与者处于头枕位置的头部向下位置包括放置在 睡眠表面，参与者的腿和脚朝向睡眠表面的上端设置，参与者的头端朝向睡眠表面的下端设置，参与者的脚端相对于头部向上 参与者结束。

公开(公告)号：US20050003006A1

公开(公告)日：2005-01-06

申请号：US10897669

申请日：2004-07-23

申请人： David Edgren ,  Shu Li ,  Patrick Wong ,  Gurdish Bhatti ,  Liang-Chang Dong ,  Si-Hong Yum

发明人： David Edgren ,  Shu Li ,  Patrick Wong ,  Gurdish Bhatti ,  Liang-Chang Dong ,  Si-Hong Yum

IPC分类号： A61K9/00 ,  A61K9/28 ,  A61K9/36 ,  A61K9/50 ,  A61K9/24

CPC分类号： A61K9/2853 ,  A61K9/0004 ,  A61K9/282 ,  A61K9/284 ,  A61K9/2866

摘要： A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

摘要翻译： 公开的组合物在溶剂中显示出对聚合物和表面活性剂具有共同的溶解性的聚合物和表面活性剂。 该组合物提供了随时间施用药物的剂型。

公开(公告)号：US06245357B1

公开(公告)日：2001-06-12

申请号：US09249700

申请日：1999-02-12

申请人： David E. Edgren ,  Shu Li ,  Gurdish Kaur Bhatti ,  Patrick S. L. Wong ,  Robert R. Skluzacek

发明人： David E. Edgren ,  Shu Li ,  Gurdish Kaur Bhatti ,  Patrick S. L. Wong ,  Robert R. Skluzacek

IPC分类号： A61K924

CPC分类号： A61K9/0004 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2866 ,  A61K9/2886

摘要： A dosage form comprising a composition comprising a drug surrounded by an interior and an exterior wall with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy.

摘要翻译： 一种剂型，其包含包含由内部和外壁包围的药物的组合物，其具有用于将药物施用于患者的出口; 并且对于指定的治疗公开了使用剂型的方法。

公开(公告)号：US09988377B2

公开(公告)日：2018-06-05

申请号：US14240681

申请日：2012-08-24

申请人： Dalibor Sames ,  Xiaoguang Li ,  Shu Li ,  Andrew Kruegel ,  Richard Karpowicz ,  Ignacio Carrera ,  Souvik Rakshit

发明人： Dalibor Sames ,  Xiaoguang Li ,  Shu Li ,  Andrew Kruegel ,  Richard Karpowicz ,  Ignacio Carrera ,  Souvik Rakshit

IPC分类号： C07D453/06

CPC分类号： C07D453/06

摘要： This invention provides a compound having the structure wherein A is a ring structure, with or without substitution; Z is present or absent and when present is wherein n is 0, 1, 2, 3, or 4; Y is —(CR11R12)—, —NH(CR11R12)—, or —O(CR11R12)—, wherein R11 and R12 are each hydrogen or combine to form a carbonyl; R1, R2, R3, R4, R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester or amide; α represents a bond, which is present or absent and when α is present, then R7 and R8 are absent; R7 and R8 are present when α is absent and are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester, amide or R5 and R7 combine to form a carbonyl or R6 and R8 combine to form a carbonyl; R9 and R10 are each hydrogen or combine to form a carbonyl; and when α is present, Z is  where n=1, Y is —(CR11R12)— where R11 and R12 are H, A is unsubstituted indole attached at the 3-position of the indole, R3, R4, R5, R6, R9 and R10 are each H, and one of R1 or R2 is H, then the other one of R1 or R2 is other than H or ethyl, or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof.

公开(公告)号：US20150056699A1

公开(公告)日：2015-02-26

申请号：US14240681

申请日：2012-08-24

申请人： Dalibor Sames ,  Xiaoguang Li ,  Shu Li ,  Andrew Kruegel ,  Richard Karpowicz ,  Ignacio Carrera ,  Souvik Rakshit

发明人： Dalibor Sames ,  Xiaoguang Li ,  Shu Li ,  Andrew Kruegel ,  Richard Karpowicz ,  Ignacio Carrera ,  Souvik Rakshit

IPC分类号： C07D453/06

CPC分类号： C07D453/06

摘要： This invention provides a compound having the structure wherein A is a ring structure, with or without substitution; Z is present or absent and when present is wherein n is 0, 1, 2, 3, or 4; Y is —(CR11R12)—, —NH(CR11R12)—, or —O(CR11R12)—, wherein R11 and R12 are each hydrogen or combine to form a carbonyl; R1, R2, R3, R4, R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester or amide; α represents a bond, which is present or absent and when α is present, then R7 and R8 are absent; R7 and R8 are present when α is absent and are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester, amide or R5 and R7 combine to form a carbonyl or R6 and R8 combine to form a carbonyl; R9 and R10 are each hydrogen or combine to form a carbonyl; and when α is present, Z is where n=1, Y is —(CR11R12)— where R11 and R12 are H, A is unsubstituted indole attached at the 3-position of the indole, R3, R4, R5, R6, R9 and R10 are each H, and one of R1 or R2 is H, then the other one of R1 or R2 is other than H or ethyl, or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof.

摘要翻译： 本发明提供具有以下结构的化合物，其中A是具有或不具有取代的环结构; Z存在或不存在，并且当存在时，其中n为0,1,2,3或4; Y是 - （CR 11 R 12） - ， - NH（CR 11 R 12） - 或-O（CR 11 R 12） - ，其中R 11和R 12各自是氢或结合形成羰基; R 1，R 2，R 3，R 4，R 5和R 6独立地为H，取代或未取代的烷基，取代或未取代的芳基，取代或未取代的杂烷基，取代或未取代的杂芳基，羟基，氨基，酯或酰胺; α表示存在或不存在且当存在α时的键，则R7和R8不存在; 当α不存在时，R 7和R 8存在，并且独立地为H，取代或未取代的烷基，取代或未取代的芳基，取代或未取代的杂烷基，取代或未取代的杂烷基，羟基，氨基，酯，酰胺或R 5和R 7结合形成羰基 或R 6和R 8结合形成羰基; R9和R10各自为氢或结合形成羰基; 当存在α时，Z是其中n = 1，Y是 - （CR11R12） - 其中R11和R12是H，A是在吲哚3位上连接的未取代的吲哚，R3，R4，R5，R6，R9 和R 10各自为H，R 1或R 2中的一个为H，则R 1或R 2中的另一个为H或乙基，或其药学上可接受的盐，非对映异构体或对映异构体。